NCT04566393 2026-01-28Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesxCuresAvailable
NCT04489433 2025-12-18Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic MelanomaNovartisNo longer available
NCT03593499 2025-05-31Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401BiogenNo longer available